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Abstract

Multidrug resistance in bacteria, defined as the ability of a bacterial strain to resist the killing effects of more
than one antibiotic, represents a major threat to global healthcare. Every year in the United States, two million
people are infected with a multidrug resistant strain of bacteria. According to the Center for Disease Control
(CDC), out of those two million people, about 35,000 will die from their infection. Thus, these multidrug
resistant diseases are considered by the CDC to be the most dangerous diseases in the world. While multidrug
resistance can occur through several different mechanisms, a major contributor to multidrug resistance are
the bacterial efflux pumps. Efflux pumps are transporters that reside in the membrane of a bacterial cell, and
they function by pumping out toxic organic compounds, including antibiotics, from the cell. These efflux
pumps often lack specificity for the compounds that they can expel from the cell which means that a single
type of efflux pump can confer resistance to many types of antibiotics all at once. When bacterial cells
produce high levels of these efflux pumps in their membranes, it can give rise to a multidrug resistance
characteristic. I intend to inhibit the efflux pump using single-stranded DNA aptamers. These aptamers
should either clog the pump opening and/or bind to the Tol C region of the pump, making it inactive. This
would allow antibiotics to once again be effective and work to their full potential.

Acknowledgements

I would like to thank Dr. Matthew Lopper for his support throughout my research project and the many hours
of planning and problem shooting. I would like to give thanks to the University of Dayton Chemistry
Department for the support of my research. I also want to thank the University of Dayton Honors program
and Dean’s Summer Fellowship program for funding my project. Thank you to everyone who has made this
project possible.

Table of Contents

Abstract

Title Page

Societal Importance

1

Multidrug Resistance

1

Bacterial Efflux Pump

2

Objective and Related Work

10

Methods and Expectations

11

References/Selected Bibliography

15

Page 1

Societal Importance
Multi-drug resistant bacterial infections represent a significant threat to our public
healthcare system. According to the CDC, about 2.8 million people in the United States
get an antibiotic resistant infection each year. Over 35,000 people will die per year from
an infection that will not respond to antibiotics.1 The rise of antibiotic-resistant strains of
bacteria can be attributed to several causes, such as the overuse of antibiotics in livestock
and the prescription of antibiotics to treat illnesses that cannot be treated with antibiotics
(this includes most viral infections). Patient compliance is also a problem. Some
individuals who are prescribed antibiotics do not finish the entire antibiotic regimen or hold
back some of their prescribed antibiotics and take them at a later occasion when they are
sick but have not received a proper medical diagnosis.2 When this occurs, it allows for the
most resistant bacteria to persist. After many decades of these practices, we are now faced
with greater numbers of antibiotic-resistant strains of bacteria that our existing antibiotics
cannot kill, and this has led to higher mortality rates from infections.

Multidrug Resistance
While there are several ways that bacteria can become multidrug resistant, one
common mechanism is through the use of bacterial efflux pumps. The efflux pump is a
transporter that is located in the membrane of the bacterial cell and it gives a bacterium the
ability to export toxins from the cell. While efflux pumps are common to many types of
bacteria, they tend to be found at higher levels in the membranes of multidrug resistant
strains.3 Bacterial efflux pumps tend to be nonspecific with respect to the compounds that
they can export which means that bacteria that overexpress them can resist the killing
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effects of many different types of antibiotics. The ESKAPE pathogens in particular are
known to utilize their efflux pumps to become multidrug resistant.4 The ESKAPE
pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae,
Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) cause over
two million illnesses and kill about 23,000 people a year. According to the CDC, these
pathogens are the leading cause of multidrug resistant infections occurring in the world.5

Bacterial Efflux Pump
There are many different families of the efflux pump that bacteria can utilize to
become antibiotic resistant. The different families are ATP-binding cassette (ABC), major
facilitator superfamily (MFS), multidrug and toxin extrusion (MATE), small multidrug
resistance (SMR), and resistance-nodulation-cell division (RND) families. Each family
differs in structure, placement, and mechanism for how they pump out substrates (Figure
1).

Figure 1. Bacterial efflux pump families. Each family of efflux differs with structure,
mechanism, and placement within the cell membrane.6
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The ABC transporter directly uses ATP as energy to function, while the other
families use electrochemical gradients as their energy source. The structure of the ABC
transporter has transmembrane domains (TMDs) that have substrate binding sites and
nucleotide-binding domains (NBDs) that the ATP will bind to and be hydrolyzed. The MFS
transporter is the most diverse family of transporters. They consist of uniporters,
symporters, and antiporters. The structure of the transporter includes two domains. To
pump substrates out, they must go through two conformational switches from inward-open
to outward-open. The MATE transporter structure has amino-terminal and carboxyterminal domains related by pseudo-twofold symmetry that form a V-shaped central cavity
open to the extracellular space. The mechanism uses hydrogen ions and sodium gradients
to efflux out substrates. The SMR transporters are small and have four transmembrane
helices that function as dimers. During the transport process, the pump has two
conformations to efflux substrates. The conformations are the inward-facing and outwardfacing states.6 The RND efflux pump goes through three different conformations to bind
substrates and efflux them. The AcrAB-TolC and MexAB-OprM are multidrug efflux
pumps that belonging to the RND superfamily and are the two most common types of
pumps.7
The RND AcrAB-TolC efflux pump is composed of three different components. It
is made up of an inner membrane transporter (AcrB), an adaptor protein (AcrA), and an
outer membrane channel (TolC). AcrA is found within the periplasm of the cell and it holds
AcrB and TolC together. AcrB is found within the inner membrane of the cell. TolC is
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found within the outer membrane. Once the protein components are assembled, they make
a transporter system that spans from the cytoplasm to the outside of the cell (Figure 2).6

Figure 2. RND bacterial efflux pump showing how AcrA, AcrB, and TolC interact with
one another in the intact efflux pump. Molecules can be pumped out of the cell through
this efflux pump either from the cytoplasm or from the periplasm. Structural model
generated from PDB ID 5O66.
The AcrB portion of the efflux pump is the active portion of the efflux pump. AcrB
is a trimer of 1,049 amino acids. It is made up of an extra-membrane headpiece and a
transmembrane region. The three transmembrane domain is arranged like a ring with a
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central hole. The hole crosses the membrane and connects to the bottom of the headpiece.
When looking at AcrB from a side view, the head piece and the transmembrane portion are
visible (Figure 3).8 This is the portion of the efflux pump that is thought to be responsible
for expelling antibiotics from the cell.

Figure 3. Side view of the AcrB portion of the pump. The funnel portion is seen at the top
of the pump.8
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The AcrB region is what allows for the large variety of substrates to be expelled.
AcrB has three different conformations which allows for the expelling of different
antibiotics. The first step is known as the access state and the vestibule opens to the
periplasm. This is where substrates can enter the vestibule, but the binding site is too small
for any substrate to bind to it. In the binding state, the vestibule remains open, and the
binding site expands enough for the substrate to bind to it. The substrates will bind to
multiple locations in the aromatic pocket inside the vestibule. The exit from the binding
site is blocked off so no substrate can get out. During the extrusion state the vestibule is
closed and the exit finally opens. The substrate is then pushed into the funnel portion due
to the binding site shrinking and expelling the substrate out into TolC (Figure 4). These
processes are fueled by the proton motive force.9

Figure 4. Birds-eye view of the AcrB mechanism. The funnel is shown where the antibiotic
will be pushed through. After exiting the funnel, the antibiotic would leave the cell through
the TolC channel.9
The TolC portion of the efflux pump is a trimer with 428 amino acids. The
appearance of the trimer looks like a hollow cylinder (Figure 5). The pump is split into β-
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domain, an α- helical domain, and a mixed α/β-domain. The top portion of the structure is
viewed to be open, and the bottom portion of the structure is tapered closed.10

Figure 5. Cross-section of the interior of TolC. It is a hollow cylinder-like structure acting
as a channel.10
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TolC has an important role in the export of substrates. During transport it is open
so substrates can fit through the channel. The opening mechanism includes the inner pair
of coils rotating around the pair next to it to dilate the entrance. The structural repeat of the
TolC portion allows for the channel to open. Figure 6 shows the different conformations
of TolC from a bird’s eye view. The mechanism of the TolC tunnel was proposed to
facilitate the first passage of substrates across two membranes.10 The assumption was made
that the substrates follow their concentration gradient to the outside of the cell. The closing
of the pump also ensures there is only one way out for the substrates to go.

Figure 6. Open and closed conformations of TolC. A) The closed conformation. B) The
open conformation.10
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With the mechanisms of AcrB and TolC put together it allows for the substrate to
be effectively pumped from the bacterial cell. The figure below shows the efflux pump
assembled with the functional mechanisms to efflux out substrates. The overall pathway of
the substrates is to bind to AcrB and be actively pumped into TolC. Once in TolC the
substrates can then follow their concentration gradient outside the cell (Figure 7).

Figure 7. The mechanism of the bacterial efflux pump.9
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Given the importance of bacterial efflux pumps in conferring multi-drug resistance
upon bacteria that overexpress them, many researchers have sought to identify inhibitors
of efflux pumps to counter multidrug resistance.11 Many researchers have investigated
inhibiting the bacterial efflux pump. Some compounds that have been evaluated are both
plant extracts and polyclonal antibodies.12,13,14 There has been evidence that there are
compounds that have an inhibitory effect on this pump.

Objective and Related Work
The goal of my research is to develop nucleic acid aptamers that will bind to and
inhibit bacterial efflux pumps that, when functional, give bacterial cells the ability to
survive in the presence of antibiotics. By blocking the activity of bacterial efflux pumps,
these nucleic acid aptamers will prevent bacterial cells from developing resistance to the
antibiotics that we use to treat infections.
Questions to be addressed:
1. Can we develop single-stranded DNA aptamers that will bind to the outer opening
of the TolC component of bacterial efflux pumps?
2. Will single-stranded DNA aptamers that bind to the efflux pump block the export
of antibiotics through the pump and will this increase the susceptibility of the
bacteria to antibiotics?
Given the role that this efflux pump plays in exporting antibiotics from the cell, we
intend to develop single-stranded DNAs that will bind to the outer opening of the pump
and block its function. There is precedence in the literature that this approach can work.
Researchers have found that antibodies that bind specifically to the TolC portion of the
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pump can sensitize the cells to antibiotics that the cells otherwise were able to tolerate.14
This research shows that macromolecules that bind to TolC can influence bacterial
susceptibility to antibiotics. I am hopeful that single-stranded DNA aptamers that bind to
TolC will have the same effect as the TolC antibodies, but with the added advantage that
single-stranded DNA aptamers are cheap and easy to synthesize in large quantities while
antibodies are not.

Methods and Expectations
I will develop single-stranded DNA aptamers that can bind to the bacterial efflux
pump through a process known as cell-SELEX. Cell-SELEX is a procedure for selecting
molecules that have desired properties from a large and diverse set of starting molecules.
The desired molecules are then amplified and passed through more selection processes to
result in a final population of molecules that in this case will have a strong binding affinity
for the outer portion of the efflux pump in the live cells.
My Cell-SELEX procedure will use live E. coli cells that overexpress the AcrAAcrB-TolC efflux pump. A mixed population of aptamers with many different DNA
sequences (~1015 different sequences) will be added to the cells and incubated for 30
minutes. This will give a chance for any aptamers that happen to have a structure that lends
itself to binding to TolC to do so. Following the incubation period, the cells will be
collected and the solution that contains the non-bound aptamers will be discarded. The cells
will be heated to release the bound aptamers. The collected aptamers will then be incubated
with cells that do not express the TolC component of efflux pump. This step represents a
negative selection step, and it will allow me to select for more specific binding between
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the aptamers and TolC. Aptamers that pass these selection steps will be passed on through
additional rounds of Cell-SELEX (Figure 8) to gradually select for the strongest binders.

Figure 8. Cell-SELEX procedure.15 Multiple rounds of Cell-SELEX will be performed.
After many rounds of Cell-SELEX has been performed, I will use growth curves to
examine the effects that the aptamer pools have on antibiotic susceptibility in live cells.
For each pool of aptamers, I will measure cell growth in the presence and absence of
antibiotics and aptamers and compare them with the growth characteristics of cells grown
with neither antibiotics nor aptamers present. This will allow me to determine if the
aptamers have an inhibiting effect on the efflux pump. By comparing the different growth
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curves to the control groups, it will allow me to measure the efflux pump inhibitory activity
of the aptamers (Figure 9).

Figure 9. Hypothetical growth curve comparing cells grown with only aptamers, cells
grown with just antibiotics, and cells grown with antibiotics and aptamers. Here, the
presence of the aptamers enhances the killing effects of the antibiotics.
Once the pools of aptamers have been identified for having activity, I will
determine which aptamer pool has the most activity and further my investigation on that
pool. The aptamers will be cloned using standard molecular cloning techniques and their
specific nucleotide sequences will be determined by conducting DNA sequencing. Once I
have identified the specific nucleotide sequence of the active aptamers, I will purchase
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synthetic versions of the aptamers from commercial sources that specialize in custom DNA
synthesis. The synthetic aptamers will be tested for their potency against a broad panel of
antibiotics and in several strains of bacteria including both Gram-positive and Gramnegative strains. This will allow me to determine the species specificity of the aptamers. I
hypothesize that aptamers that have been selected in cell-SELEX using E. coli will show
greatest activity against E. coli and related bacteria and that they will be less active against
evolutionarily distant bacterial strains.
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